MarketFriction

Ganga Pharmaceuticals Ltd

BSE 539680 · Pharmaceuticals
₹12.50 +4.17%
BSE close2026-09-08
Market cap₹7.39 Cr.
P/E73.9

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Sales1.141.231.251.241.351.231.321.421.311.331.371.46
Expenses1.071.281.231.231.281.301.271.411.421.331.391.39
Operating Profit0.07-0.050.020.010.07-0.070.050.01-0.110.00-0.020.07
OPM %6.14%-4.07%1.60%0.81%5.19%-5.69%3.79%0.70%-8.40%0.00%-1.46%4.79%
Other Income0.070.190.110.150.120.180.090.150.290.140.150.13
Interest0.090.100.100.090.120.070.090.090.090.090.070.07
Depreciation0.030.030.030.030.030.030.030.020.020.020.030.03
Profit before tax0.020.010.000.040.040.010.020.050.070.030.030.10
Tax %50.00%100.00%25.00%25.00%0.00%50.00%20.00%57.14%-66.67%33.33%20.00%
Net Profit0.020.000.000.030.030.010.020.030.020.060.020.08
EPS in Rs0.050.000.000.070.070.020.050.060.040.120.030.14
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales2.442.452.632.733.182.992.272.322.472.582.482.67
Expenses2.192.152.322.412.762.612.242.282.472.532.602.63
Operating Profit0.250.300.310.320.420.380.030.040.000.05-0.120.04
OPM %10.25%12.24%11.79%11.72%13.21%12.71%1.32%1.72%0.00%1.94%-4.84%1.50%
Other Income0.170.140.160.150.140.170.250.260.300.240.440.28
Interest0.330.330.320.280.250.240.190.190.190.180.180.13
Depreciation0.040.040.040.060.050.050.050.050.060.050.050.06
Profit before tax0.050.070.110.130.260.260.040.060.050.060.090.13
Tax %40.00%28.57%27.27%23.08%30.77%23.08%50.00%16.67%40.00%33.33%11.11%23.08%
Net Profit0.030.050.070.090.190.190.020.040.040.050.080.10
EPS in Rs0.130.120.170.220.470.470.050.100.100.100.170.17
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth1%3%3%8%
Compounded Profit Growth7%38%36%25%
Stock Price CAGR5%20%5%-14%
Return on Equity2%1%1%1%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital2.334.064.064.064.064.064.064.064.064.844.845.91
Reserves0.310.740.810.911.091.291.311.351.392.212.292.40
Borrowings2.142.192.142.051.871.471.731.931.831.361.421.09
Other Liabilities0.610.350.601.220.740.750.560.660.710.240.420.25
Total Liabilities5.397.347.618.247.767.577.668.007.998.658.979.65
Fixed Assets0.650.620.620.820.800.760.720.680.640.610.660.65
CWIP0.000.000.000.000.000.000.000.000.000.000.000.00
Investments0.050.500.000.000.090.090.090.090.090.090.000.00
Other Assets4.696.226.997.426.876.726.857.237.267.958.319.00
Total Assets5.397.347.618.247.767.577.668.007.998.658.979.65
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity0.27-1.050.050.240.11-0.31-0.18-0.21-0.04-1.26-0.58-1.31
Cash from Investing Activity-0.18-0.830.62-0.140.280.370.280.190.490.131.180.24
Cash from Financing Activity-0.061.90-0.33-0.36-0.45-0.29-0.100.03-0.441.14-0.330.82
Net Cash Flow0.030.020.33-0.26-0.05-0.220.000.010.010.000.27-0.24
Free Cash Flow0.23-1.060.01-0.020.08-0.32-0.20-0.22-0.05-1.28-0.68-1.35
CFO/OP104%-347%29%88%40%-66%-567%-500%-2,480%467%-3,200%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days109.20140.04173.48211.25141.18130.62131.85140.02131.52130.16133.93128.50
Inventory Days288.16374.86385.66358.71341.26296.56332.62330.51347.34362.08353.03328.50
Days Payable118.0198.65182.50330.39163.21159.69129.52152.32170.7329.2083.7733.69
Cash Conversion Cycle279.35416.26376.64239.56319.23267.49334.96318.21308.13463.04403.19423.31
Working Capital Days142.11467.80428.84417.14387.96449.23477.56503.45477.31639.46731.47855.77
ROCE %8.03%6.80%6.14%5.84%7.26%7.23%3.30%3.46%3.28%3.06%3.18%2.90%
Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Promoters66.71%66.71%66.71%66.71%66.71%66.71%66.71%56.02%56.02%56.02%50.91%50.91%
Public33.29%33.29%33.29%33.29%33.29%33.29%33.28%43.98%43.98%43.98%49.09%49.09%
No. of Shareholders354354356356355356359363365368366365

Fundamentals

Market Cap₹ 7.39 Cr.
Current Price₹ 12.5
Stock P/E73.9
Book Value₹ 14.1
ROCE2.90 %
ROE1.30 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)8%
Compounded Profit Growth (TTM)25%
Standalone figures.
Valuation
Market capRs 7 Cr
Enterprise valueRs 8 Cr
P/E (TTM)73.89x
Price to book0.89x
Price to sales2.77x
EV / EBITDA26.31x
EV / EBIT32.38x
EV / sales3.15x
Earnings yield1.35%
P/E, 3-year average122.85x
P/B, 3-year average1.07x
P/E, 5-year average122.81x
P/B, 5-year average1.01x
Profitability
Operating margin (excl. other income)1.50%
Operating margin (incl. other income)11.98%
EBITDA margin11.98%
Pre-tax margin4.87%
Net profit margin3.75%
ROE1.30%
ROCE2.90%
ROA1.07%
ROE, 3-year average1.07%
ROCE, 3-year average3.05%
ROA, 3-year average0.86%
ROE, 5-year average0.94%
ROCE, 5-year average3.18%
ROA, 5-year average0.72%
ROIC (approx.)2.14%
Tax rate23.08%
Other income / net worth3.37%
Growth
Sales growth (latest year)7.66%
Profit growth (latest year)25.00%
Sales CAGR, 3 years2.63%
Sales CAGR, 5 years3.30%
Profit CAGR, 3 years35.72%
Profit CAGR, 5 years37.97%
Per share
EPS (TTM)Rs 0.17
EPS (latest year)Rs 0.17
EPS, 3-year averageRs 0.15
EPS, 5-year averageRs 0.13
Book value per shareRs 14.06
Sales per shareRs 4.52
Cash flow per shareRs -2.22
Free cash flow per shareRs -2.28
Efficiency
Asset turnover0.28x
Fixed asset turnover4.11x
Inventory turnover1.12x
Inventory days326 days
Debtor days129 days
Debtors turnover2.84x
Creditor days34 days
Cash conversion cycle423 days
Working capital days856 days
Leverage
Total debtRs 1 Cr
Cash and bankRs 0 Cr
Net debtRs 1 Cr
Debt to equity0.13x
Net debt / EBITDA3.22x
Interest coverage2.00x
Owners' fund to total sources86.11%
Debt to assets11.30%
Cash flow
Cash from Operating Activity (latest year)Rs -1 Cr
Cash from Investing Activity (latest year)Rs 0 Cr
Cash from Financing Activity (latest year)Rs 1 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs -1 Cr
FCFE (approx.: FCF + change in debt)Rs -2 Cr
Cash from ops / profit, 5 years-10.97x
Statement figures
Net sales (TTM)Rs 3 Cr
Net sales (latest year)Rs 3 Cr
Operating profit excl. other income (latest year)Rs 0 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 0 Cr
PBDT (TTM)Rs 0 Cr
Profit before tax (TTM)Rs 0 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs 0 Cr
Net profit (latest year)Rs 0 Cr
Depreciation (TTM)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 1 Cr
Total expenditure (latest year)Rs 3 Cr
Total income (latest year)Rs 3 Cr
Share capitalRs 6 Cr
ReservesRs 2 Cr
Shareholders' fundsRs 8 Cr
Total assetsRs 10 Cr
Net blockRs 1 Cr
ReceivablesRs 1 Cr
InventoryRs 1 Cr
Other liabilitiesRs 0 Cr
Shares outstanding (crore)0.59
Ownership
Promoter holding50.91% (-5.11 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 73.9 is at the 38th percentile of its own 5.0-year range (median 119.7, low 21.9, high 380.6).
P/B 0.89 is at the 36th percentile (median 1.06).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
Period539680Nifty 50Difference
3 years-15.0%+14.2% -29.1 pts
5 years+108.3%+27.9% +80.4 pts

Red flags

F-score 5 of 8
explainWeak cash conversion Cash from operations was -1370% of net profit over the last 3 years
explainHigh accruals Profit exceeded operating cash by 15% of total assets in 2026
explainShare dilution Share count up 23% in a year, 44% in three
lookProfit leans on other income Other income was 215% of pre-tax profit in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Mar 2026
Sales ₹1 Cr +2.8% vs Mar 2024. Net profit ₹0 Cr +166.7%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Ganga Pharmaceuticals Ltd?

Ganga Pharmaceuticals Ltd (539680) has a market capitalisation of Rs 7.39 Cr. at the 2026-09-08 close.

What is the P/E ratio of Ganga Pharmaceuticals Ltd?

Ganga Pharmaceuticals Ltd trades at a P/E of 73.9 on trailing twelve-month profit, at the 2026-09-08 close.

What were Ganga Pharmaceuticals Ltd's latest quarterly results?

In the Mar 2026 quarter, Ganga Pharmaceuticals Ltd sales was Rs 1 Cr (+2.8% vs Mar 2024) and net profit was Rs 0 Cr.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03